Octreotide

Octreotide is a synthetic cyclic octapeptide that mimics the pharmacological actions of native somatostatin with dramatically enhanced metabolic stability. It was the first somatostatin analog developed for clinical use and remains the prototype against which newer analogs are compared.

The compound preferentially binds somatostatin receptor subtypes SSTR2 and SSTR5, which mediate most of the clinically relevant effects including suppression of growth hormone, glucagon, insulin, and various gastrointestinal hormones. The disulfide-bridged cyclic structure maintains the bioactive conformation while D-amino acid substitutions provide resistance to enzymatic degradation.

Octreotide is approved for multiple indications including acromegaly (GH-secreting pituitary tumors), carcinoid syndrome, and VIPomas. Long-acting release (LAR) formulations enable once-monthly dosing for chronic therapy, significantly improving patient convenience.

Radiolabeled octreotide (octreoscan) revolutionized imaging of neuroendocrine tumors that express somatostatin receptors, enabling detection of primary and metastatic disease. More recently, DOTA-modified octreotide conjugated with therapeutic radioisotopes (PRRT - peptide receptor radionuclide therapy) provides targeted treatment for these tumors.